Genelux is like Amgen, but specializing in engineered vaccinia viruses to fight a broad range of solid cancers.

Genelux (GNLX) is a clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies. As such, it does not currently sell products directly to individuals. Instead, its primary business model involves developing product candidates and then entering into licensing agreements or joint ventures with other companies for the further development and commercialization of these candidates.

Therefore, Genelux's major "customers" or partners are other companies. These include:

• Newsoara BioPharma Co. Ltd. (Newsoara): Newsoara holds an exclusive license to research, develop, and commercialize Olvi-Vec in China (mainland China, Taiwan, Hong Kong, and Macau). Newsoara is responsible for all costs and expenses related to these activities in the territory. (Newsoara is a private company).
• V2ACT Therapeutics, LLC (V2ACT): V2ACT is a joint venture formed by Genelux with TVAX Biomedical Inc. The purpose of V2ACT is to develop and commercialize V2ACT Immunotherapy, which combines an oncolytic virus (e.g., Olvi-Vec) and neoantigen-primed adoptive cell therapy for cancer. (V2ACT is not a public company).
• ELIAS Animal Health LLC (ELIAS): ELIAS holds an exclusive, worldwide license to research, develop, use, and commercialize veterinary products containing the oncolytic virus V-VET1 for cancer in non-human animals. ELIAS is solely responsible for all costs and expenses related to these activities. (ELIAS is a private company).

Thomas Zindrick, J.D. President and Chief Executive Officer

Mr. Zindrick has served as President and Chief Executive Officer of Genelux since 2014 and as Chairman since July 2021. He brings over 30 years of executive experience in the life sciences and biotechnology sector. He currently serves as Executive Chair of Aeromics, Inc., a clinical-stage pharmaceutical company. His past board memberships include Amitech Therapeutic Solutions, Inc. and DNX Biopharmaceuticals, Inc. From 1993 to 2009, Mr. Zindrick held positions of increasing responsibility at Amgen, including Vice President Associate General Counsel and Chief Compliance Officer. Before Amgen, he was an attorney at The Dow Chemical Company.

Matt Pulisic, MBA Chief Financial Officer

Mr. Pulisic was appointed Chief Financial Officer of Genelux effective January 30, 2025. He has over 19 years of finance and commercial experience within the biopharmaceutical industry. Prior to joining Genelux, he served as Vice President of Finance at Arrowhead Pharmaceuticals from 2020 to 2025, where he was involved in financial planning and analysis, establishing a commercial manufacturing facility, and driving operational improvements during the company's transition to a pre-commercial stage. He also held the position of Head of Finance at HARMAN International from 2019 to 2020. Mr. Pulisic began his career at Amgen in 2006 as a Research Associate and later moved into various finance leadership roles, including Finance Director of Amgen Worldwide and Head of Capital Finance.

Jason Litten, M.D. Chief Medical Officer

Dr. Litten joined Genelux as Chief Medical Officer effective January 2, 2026, where he is responsible for overseeing clinical development and medical strategy. He brings over 20 years of experience in biopharmaceutical development, particularly in oncology, covering biologics, small molecules, and cell therapies. His previous roles include Chief Medical Officer at Chimeric Therapeutics, Ltd. and Artiva Biotherapeutics, as well as leadership positions at Optera Therapeutics, Juno Therapeutics, Clovis Oncology, and Amgen.

Joseph Cappello, Ph.D. Chief Technical Officer

Dr. Cappello serves as the Chief Technical Officer for Genelux. He is also identified as the VP, Pharmaceutical Development.

Eric Groen, J.D. General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development

Mr. Groen was appointed to his current role at Genelux, effective July 1, 2025. He has over two decades of leadership experience in the life sciences industry. Before joining Genelux, he was General Counsel of Rani Therapeutics. Mr. Groen also spent 20 years in the legal department at Amgen, where he gained extensive experience in business development transactions, including Amgen's $10 billion acquisition of Onyx Pharmaceuticals.

Key Risks to Genelux's Business

1. Clinical Trial Failure and Regulatory Approval

   The success of Genelux is highly dependent on the successful completion of its clinical trials and the subsequent receipt of regulatory approvals for its product candidates, particularly Olvi-Vec. As a clinical-stage biopharmaceutical company, failure to demonstrate the efficacy and safety of Olvi-Vec or other candidates in ongoing or planned trials (such as the Phase 3 registration trial for Olvi-Vec in platinum-resistant/refractory ovarian cancer, or the planned Phase 2 for NSCLC) would significantly impede the company's ability to commercialize its products and generate revenue. Additionally, delays in the clinical trial process or the inability to obtain necessary regulatory approvals from agencies like the U.S. Food and Drug Administration (FDA) could substantially delay or prevent market entry, leading to significant financial and operational setbacks.

2. Manufacturing Process Changes and Regulatory Acceptance

   Genelux has undertaken significant changes to its manufacturing process for Olvi-Vec, transitioning from chicken embryo fibroblasts (CEF) to a mammalian host cell and modifying its purification methods. These changes have led to several amendments to its Investigational New Drug (IND) application and multiple rounds of comments and responses with the FDA regarding comparability and manufacturing. There is an inherent risk that these revised manufacturing processes may not be fully accepted by regulatory authorities, or that unforeseen issues may arise with product quality, comparability, or scalability under the new process. Such challenges could lead to further regulatory delays, increased costs, or potentially halt the development and commercialization of Olvi-Vec.

3. Heavy Dependence on Olvi-Vec and Limited Advanced Pipeline

   Genelux's business is currently heavily concentrated on the development and potential commercialization of its lead product candidate, Olvi-Vec. While the company possesses an extensive library of potential candidates through its CHOICE platform and mentions V2ACT Immunotherapy and V-VET1, Olvi-Vec is the most advanced, with a Phase 3 registration trial underway. Other candidates, such as V2ACT Immunotherapy, have had their Phase 1b/2a clinical trial authorized but are "not yet scheduled to be initiated." This signifies a substantial reliance on the success of Olvi-Vec. A significant setback, failure, or unexpected delay in the development or regulatory approval of Olvi-Vec would have a disproportionately negative impact on the company's financial condition, operational results, and future prospects, given the relatively earlier stage or lack of active progression of its other pipeline assets.

Genelux's primary product, Olvi-Vec, targets several aggressive solid tumor types, representing significant addressable markets. The company's pipeline also includes V2ACT Immunotherapy for pancreatic cancer.

Olvi-Vec (Olvi-Vec(olvimulogene nanivacirepvec))

Olvi-Vec is being developed for multiple indications, including platinum-resistant/refractory ovarian cancer, non-small cell lung cancer, and small cell lung cancer. Genelux has indicated that these indications collectively represent a multi-billion dollar market opportunity.

• Platinum-Resistant/Refractory Ovarian Cancer (PRROC): The global ovarian cancer treatment drugs market size is expected to reach approximately $5.45 billion by 2033. The U.S. ovarian cancer drugs market was valued at an estimated $1.3 billion in 2024 and is projected to grow to approximately $2.4 billion by 2034. The market for High-Grade vs. Low-Grade Serous Ovarian Cancer in the seven major markets (7MM - United States, EU4 (Germany, France, Italy, Spain), United Kingdom, and Japan) is projected to increase from $3,012 million in 2025 to $5,703 million by 2034.
• Non-Small Cell Lung Cancer (NSCLC): The global non-small cell lung cancer market was estimated at $20.2 billion in 2024 and is expected to reach $53.9 billion by 2034. In the United States, the NSCLC market was valued at $8.2 billion in 2024 and is projected to reach approximately $12.5 billion by 2030. The NSCLC market across the 7MM is expected to grow from $32,442 million in 2025 to $64,819 million in 2034.
• Small Cell Lung Cancer (SCLC): The global small cell lung cancer therapeutics market was estimated at $6.52 billion in 2025 and is projected to increase to approximately $17.59 billion by 2033. Another estimate indicates the global market size for SCLC therapeutics is valued at $7.25 billion in 2025 and is predicted to grow to approximately $22.86 billion by 2035. In the United States, the SCLC treatment market is estimated to be $527.0 million in 2025 and is anticipated to reach $1.5 billion by 2035.

V2ACT Immunotherapy

• Pancreatic Cancer: The global pancreatic cancer treatment market size was estimated at $2.92 billion in 2024 and is projected to reach $5.84 billion by 2030. Another report valued the global pancreatic cancer market at $3.28 billion in 2025, with a projection to exceed $12.05 billion by 2035. For the United States, the pancreatic cancer treatment market size was an estimated $1.02 billion in 2024 and is projected to grow to approximately $5.46 billion by 2035.

Here are 3-5 expected drivers of future revenue growth for Genelux (GNLX) over the next 2-3 years:

• Advancement and Potential Market Approval of Olvi-Vec for Platinum-Resistant/Refractory Ovarian Cancer (PRROC): Genelux has successfully met the preestablished endpoint for its Phase 2 clinical trial of Olvi-Vec in PRROC and commenced enrollment in its Phase 3 registration trial in the third quarter of 2022. The successful completion of this pivotal trial and subsequent regulatory approval would be a significant driver for commercialization and revenue generation.
• Expansion of Olvi-Vec into New Indications and Geographies through Strategic Partnerships: The license agreement with Newsoara BioPharma Co. Ltd. grants an exclusive license for Olvi-Vec in China for all human diagnostic, prophylactic, and therapeutic uses. Newsoara is anticipated to initiate a Phase 1 clinical trial of Olvi-Vec in patients with recurrent SCLC in the first half of 2023, followed by trials in recurrent NSCLC and recurrent ovarian cancer in China. Additionally, a Phase 2 clinical trial for intravenously delivered Olvi-Vec in recurrent NSCLC patients in the United States, fully funded by Newsoara, is expected to begin regulatory study start-up in the first half of 2023. These expansions into new indications and the substantial Chinese market represent considerable growth opportunities.
• Development and Commercialization of V-VET1 for Animal Cancer Treatments via the ELIAS Animal Health LLC Partnership: Genelux has granted ELIAS Animal Health LLC an exclusive, worldwide, and royalty-bearing license to research, develop, and commercialize V-VET1 for the diagnosis, prevention, and treatment of cancer in non-human animals. ELIAS is solely responsible for all associated costs and expenses, including studies and clinical trials, opening a new revenue stream from the veterinary medicine market.
• Progression of V2ACT Immunotherapy into Clinical Development for Pancreatic Cancer: V2ACT Therapeutics, LLC, a joint venture, has received FDA authorization for the initiation of a Phase 1b/2a clinical trial to investigate V2ACT Immunotherapy as a treatment for newly-diagnosed, surgically-resectable pancreatic cancer. Although not yet initiated, the advancement of this new product candidate into clinical trials could provide significant future revenue growth by addressing high unmet medical needs.

Share Issuance

• In May 2023, Genelux announced a private placement of 1,665,247 shares of its common stock at $20.00 per share, generating gross proceeds of approximately $33 million.
• In January 2026, Genelux priced an underwritten public offering of 6,666,667 shares of common stock at $3.00 per share, with expected gross proceeds of approximately $20.0 million.

Inbound Investments

• In September 2021, Genelux entered a License Agreement with Newsoara BioPharma Co. Ltd., granting an exclusive license for Olvi-Vec in China. Newsoara is solely responsible for all research, development, manufacturing, and commercialization costs in the territory, and is funding a Phase 2 clinical trial of intravenously delivered Olvi-Vec for recurrent NSCLC in the United States, anticipated to begin in the first half of 2023.
• In November 2021, Genelux entered into a License Agreement with ELIAS Animal Health LLC, granting an exclusive, worldwide, royalty-bearing license for V-VET1 in non-human animals. ELIAS is solely responsible for all costs and expenses for the research, development, and commercialization of these licensed products.

Outbound Investments

• Genelux formed V2ACT Therapeutics, LLC, a joint venture with TVAX Biomedical Inc., to develop and commercialize the V2ACT Immunotherapy product candidate.

Capital Expenditures

• Genelux's capital expenditures in the most recent quarter totaled approximately -$0.517 million USD.
• Over the last 12 months, capital expenditures were approximately -$758,000.
• The company invested in a new in-house manufacturing process for Olvi-Vec, including changes from chicken embryo fibroblasts (CEF) host cells to mammalian host cells and modifications to the purification process, with related FDA communications occurring from June 2021 to July 2022.